Rapport Therapeutics, INC Form 4 insider transactions

Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.

NASDAQ
Third Rock Ventures V, L.P. and 5 others reported changes in beneficial ownership of Rapport Therapeutics, Inc. common stock on October 30, 2026.
NASDAQ
James Healy, a Director of Rapport Therapeutics, Inc., purchased 969,480 shares of common stock on October 28, 2026 for $21.00 per share.
NASDAQ
Abraham Ceesay, Chief Executive Officer and a Director of Rapport Therapeutics, Inc., sold 2,210 shares of common stock on October 21, 2026 for $29.16 per share.
NASDAQ
Ramiro Sanchez, a Director of Rapport Therapeutics, Inc., purchased 3,600 shares of common stock on October 23, 2026 for $27.35 per share.
NASDAQ
Paul M Silva, a Director of Rapport Therapeutics, Inc., purchased 3,680 shares of common stock on October 22, 2026 for $27.07 per share.
NASDAQ
Wendy B. Young, a Director of Rapport Therapeutics, Inc., purchased 3,789 shares of common stock on October 22, 2026 for $26.39 per share.
NASDAQ
Steven M Paul, a Director of Rapport Therapeutics, Inc., purchased 35,714 shares of common stock on October 22, 2026 for $27.28 per share.
NASDAQ
John Maraganore, a Director of Rapport Therapeutics, Inc., purchased 9,411 shares of common stock on October 22, 2026.
NASDAQ
Troy A. Ignelzi, Chief Financial Officer of Rapport Therapeutics, Inc., purchased 5,500 shares of common stock on October 21, 2026 for $26.10 per share.
NASDAQ
Abraham Ceesay, Chief Executive Officer and a Director of Rapport Therapeutics, Inc., sold 4,522 shares of common stock on October 6, 2026.
NASDAQ
Cheryl Gault, Chief Operating Officer of Rapport Therapeutics, Inc., sold 10,000 shares of common stock on September 30, 2026.
NASDAQ
Abraham Ceesay, Chief Executive Officer and a Director of Rapport Therapeutics, Inc., sold 2,210 shares of common stock on September 23, 2026.
NASDAQ
Abraham Ceesay, Chief Executive Officer and a Director of Rapport Therapeutics, Inc., sold 8,210 shares of common stock on September 8, 2026.
NASDAQ
Abraham Ceesay, Chief Executive Officer and a Director of Rapport Therapeutics, Inc., sold 18,921 shares of common stock on August 25, 2026 for $49.57 per share.
NASDAQ
Krishnaswamy Yeleswaram, Chief Development Officer of Rapport Therapeutics, Inc., sold 404 shares of common stock on August 19, 2026 for $49.90 per share.
NASDAQ
Abraham Ceesay, Chief Executive Officer and a Director of Rapport Therapeutics, Inc., sold 51,499 shares of common stock on August 10, 2026.
NASDAQ
Abraham Ceesay, Chief Executive Officer and a Director of Rapport Therapeutics, Inc., sold 2,210 shares of common stock on July 27, 2026.
NASDAQ
Abraham Ceesay, Chief Executive Officer and a Director of Rapport Therapeutics, Inc., sold 8,210 shares of common stock on July 14, 2026.
NASDAQ
Rapport Therapeutics COO Cheryl Gault sold a total of 9,900 shares of common stock across multiple transactions on June 30, 2026, pursuant to a Rule 10b5-1 trading plan.
NASDAQ
Rapport Therapeutics CEO Abraham Ceesay sold a significant number of shares under pre-arranged trading plans.
NASDAQ
Director John Maraganore was granted 15,200 stock options in Rapport Therapeutics, Inc. as part of standard equity compensation.
NASDAQ
Director Robert J. Perez was granted 15,200 stock options in Rapport Therapeutics, Inc. as part of standard equity compensation.
NASDAQ
Director Steven M. Paul was granted 15,200 stock options in Rapport Therapeutics, Inc. as part of standard equity compensation.
NASDAQ
Director Paul M. Silva was granted 15,200 stock options in Rapport Therapeutics, Inc. as part of standard equity compensation.
NASDAQ
Director James Healy was granted 15,200 stock options in Rapport Therapeutics, Inc. as part of standard equity compensation.
NASDAQ
Director Reid M. Huber was granted 15,200 stock options in Rapport Therapeutics, Inc. as part of standard equity compensation.
NASDAQ
Director Wendy B. Young was granted 15,200 stock options in Rapport Therapeutics, Inc. as part of standard equity compensation.
NASDAQ
Director Ramiro Sanchez was granted 15,200 stock options in Rapport Therapeutics, Inc. as part of standard equity compensation.
NASDAQ
Third Rock Ventures V, L.P. sold 18,572 shares of Rapport Therapeutics, Inc. (RAPP) at a weighted average price of $40.047.
NASDAQ
Third Rock Ventures V, L.P. sold 133,618 shares of Rapport Therapeutics, Inc. (RAPP) at a weighted average price of $40.24 per share.